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Abstract 
Purpose: To investigate the therapeutic effect of Rhizoma Drynariae extract (RDE) on ovariectomy-
induced osteoporosis in rats.  
Methods: Female Sprague-Dawley rats were randomly assigned to a sham-operated group (control) 
and five ovariectomy (OVX) subgroups: OVX with vehicle (OVX), OVX with 17ß-estradiol (E2, 25 
µg/kg/day), and OVX with RDE doses (40, 80, and 160 mg/kg/day). Daily oral administration of E2 or 
RDE started 4 weeks after OVX and lasted for 16 weeks. The bone mineral density (BMD) of the L4 
vertebrae and right femurs was estimated. The length of each femur was measured with a micrometer 
gauge, and the center of the diaphysis determined. Three representatives L4 vertebrae were selected to 
evaluate the trabecular microarchitecture. Serum alkaline phosphatase (ALP), urinary calcium (U-Ca), 
urinary phosphorus (U-P), urinary creatinine (Cr) and osteocalcin (OC) levels were measured.  
Results: The study showed that high-dose of RDE significantly inhibited the bone mineral density 
(BMD) reduction of L4 vertebrae (0.20 ± 0.02 g/cm3, p < 0.05) and femurs (0.18 ± 0.02 g/cm3, p < 0.05) 
caused by OVX and prevented the deterioration of trabecular microarchitecture (p < 0.05), which were 
accompanied by a significant decrease in skeletal remodeling (p < 0.05) as evidenced by the lower 
levels of bone turnover markers. High-dose of RDE improved morphometric parameters, namely, Tb-N 
(3.8 ± 0.2 mm, p < 0.05), Tb-Th (0.083 ± 0.011 mm, p < 0.05) and Tb-Sp (0.19 ± 0.01 mm, p < 0.05) in 
L4 vertebrae significantly. The present study indicates that the administration of RDE at higher doses 
over a 16-week period can prevent OVX-induced osteoporosis in rats without hyperplastic effects on the 
uterus. 
Conclusion: Thus, RDE is a potential natural alternative for postmenopausal osteoporosis treatment in 
elderly women. 
 
Keywords: Rhizoma Drynariae, Postmenopausal osteoporosis, Ovariectomy, Bone mineral density, 
Morphometric 
 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




Osteoporosis is a systemic skeletal disease 
characterized by reduced bone mass and micro-
architectural deterioration of bone tissue with a 
consequent increase in bone fragility and 
susceptibility to fractures [1]. According to data 
released by the World Health Organization 
(WHO), osteoporosis affects approximately 
million people throughout Europe, the USA, and 
Japan [2]. The incidence of osteoporosis 
increases dramatically with life expectancy. 
Accordingly, the risk of osteoporotic fractures 
and their associated costs is rising rapidly due to 
population aging [3]. In the elderly, hip fractures 
are closely associated with mortality [4]. 
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Hormone deficiency is known to impair 
cancellous metaphyseal bone and reduce BMD 
in humans and animals; therefore, estrogen 
deficiency in post-menopausal women has been 
regarded as a critical cause of this population’s 
susceptibility to osteoporosis [5]. Osteoporosis is 
twice as common in women as in men [6], and 
approximately one in three women over 50 years 
old experiences an osteoporotic fracture in her 
life time [7]. 
 
Clinically, hormone replacement therapy (HRT) 
has been a popular therapeutic strategy 
designed for postmenopausal osteoporosis [8,9]. 
However, the long-term application of HRT has 
potential malignant effects on reproductive 
tissues [10-13]. Other medicines that stimulate 
bone formation (e.g., growth hormone, sodium 
uoride, and parathyroid hormone) or inhibit bone 
resorption (e.g., bisphosphonates and calcitonin) 
may prevent bone loss progression in 
established osteoporosis. However, these 
medications are not effective for a large 
proportion of the world population, especially in 
developing countries, and these drugs have side 
effects, such as gastrointestinal reactions, 
cancers, osteonecrosis of the jaw, and reduced 
skeletal strength [14,15]. Consequently, to 
substitute or reduce the medicines used 
currently, there are efforts to develop new drugs 
with improved therapeutic efficacy, fewer 
undesirable side effects, and lower price. 
 
R. drynariae, the dried rhizome of Drynaria 
fortune (Kunze) J.Sm. (Gu-Sui-Bu in Chinese), 
has been widely used as a kidney-tonifying and 
anti-osteoporosis herb for the treatment of 
nephrasthenia syndrome [16], osteoporosis 
[17,18] and bone fracture [19] for thousands of 
years in China. Therefore, the aim of the present 
study was to systematically evaluate the effect of 




Preparation of Rhizoma Drynariae extract 
 
The herbal samples of Rhizoma Drynariae were 
collected from Bozhou City, Anhui Province in 
China in July 2014. Taxonomic identification of 
the plant was performed by Professor Kang Hu 
of Shandong University of Traditional Chinese 
Medicine, in China. A voucher specimen (no. 
RDE 201409015) was deposited in Shandong 
University of Traditional Chinese Medicine, China 
for future reference. 
 
One batch of herbal samples Rhizoma drynariae 
was dried in an oven. Aqueous extract of RDE 
was obtained by steeping the dried Rhizoma 
drynariae in water at 60 oC three times for 1 h 
each. Then drying the extracted fluid in an oven 
and freeze-drying the last extract. The same 
batch was extracted for 3 times. One gram 
powder was equivalent to about 1.5 g crude 
samples. The yield was 66.67 %. 
 
Animals and treatment 
 
Healthy three-month-old female Sprague-Dawley 
rats (weighing 220 ± 10 g).Were provided by the 
Experimental Animal Center of Shandong 
Province (Certificate no. SYXK 2004-0003). The 
animals had free access to feed and water, and 
were allowed to acclimatize for at least one week 
before use. The rat experiment was approved by 
the Animal Care and Use Committee of 
Shandong University of Traditional Chinese 
Medicine (approval ref no. 20120804) and was 
carried out in compliance with the Directive 
2010/63/EU on the handling of animals used for 
scientific purposes [20]. 
 
60 rats were randomly divided into six groups of 
ten individuals: a sham-operated group (control) 
and five ovariectomy (OVX) subgroups, that is, 
OVX with vehicle (OVX), OVX with 17ß-estradiol 
(E2, 25 mg/kg/day), and OVX with RDE doses 
(40, 80 and 160 mg/kg/day). Daily oral 
administration of E2 or RDE started 4 weeks after 
OVX and lasted for 16 weeks. 
 
Bone mineral density measurement 
 
The BMD of the L4 vertebrae and right femurs 
was estimated using dual-energy x-ray 
absorptiometry scanning (DEXA, GE Healthcare, 
USA) with small animal measurement. The 
measurements were expressed as grams of 
mineral contents per cm2 of surface area. Scans 
were performed by the same blinded technician. 
 
Three-point bending test 
 
Before mechanical testing, the rats were 
sacrificed by cervical spondylosis. Then the left 
femurs were slowly thawed at room temperature. 
The length of each femur (distance from the 
intermalleolar to the intercondylar region) was 
measured with a micrometer, and the center of 




Based on the BMD, three representatives L4 
vertebrae from each group were selected to 
evaluate the trabecular microarchitecture using 
eXplore Locus SP preclinical specimen 
microcomputed tomography (MicroCT, GE 
Healthcare, USA). Before the scans, the bones 
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were positioned with gauze in the sample holder 
and allowed to reach room temperature. The L4 
vertebrae were scanned from the anterior 
endplate in the posterior endplate direction (22 
um/slice). The isotropic voxel resolution of bone 
was 22 um3. The volume of interest (VOI) was 
selected as a region 25 slices away from the 
anterior endplate to the posterior endplate, 
ranging to 125 slices. The three-dimensional 
images were reconstructed with the purpose of 
visualization and display. After analyzing the 
VOI, morphometric bone parameters, including 
trabecular number (Tb-N), trabecular separation 
(Tb-Sp), trabecular thickness (Tb-Th) were 
obtained. The VOI analysis was performed 
blindly by the same operator. 
 
Biochemical analysis of serum and urine 
specimens 
 
The serum of rats were collected by picking 
eyeball, and the urine of rats were collected by 
stimulating back. The levels of serum alkaline 
phosphatase (ALP), urinary calcium (U-Ca), 
urinary phosphorus (U-P), and urinary creatinine 
(Cr) were measured on an automatic analyzer 
(Ciba-Corning 550, USA) using a diagnostic 
reagent kit. Serum osteocalcin (OC) 
concentration was determined using a rat OC 




The data are expressed as the mean ± SD. 
Statistical analysis was performed using one-way 
ANOVA combined with Bonferroni’s multiple 
comparison test using SPSS 16.0. Differences 





BMD of L4 vertebrae and femur 
 
The BMD of the L4 vertebrae and femurs is 
presented in Table 1. These results demonstrate 
that OVX significantly decreased the BMD in the 
L4 vertebrae and femurs compared to the sham 
group (p < 0.05). Compared to the OVX group, 
RDE treatment significantly prevented the BMD 
decrease in OVX-induced L4 vertebrae and 
femurs (all p < 0.05) in a dose-dependent 
manner. E2 also significantly increased the BMD 
of the L4 vertebrae and femurs (both p < 0.05), 
which was similar to that observed in the H-RDE 
group (p > 0.05). 
 
Mechanical testing of femur 
 
The results of the femur mechanical testing are 
presented in Table 2. Compared with the sham 
group, 16 weeks of estrogen deficiency 
significantly decreased the maximum load and 
maximum stress (both p < 0.05). Meanwhile, 
higher dosage of RDE treatments (80 or 160 
mg/kg/day) markedly prevented the OVX-
induced tendency to decrease these parameters 
(p < 0.05). E2 also increased these 
biomechanical parameters, which were 
significantly higher than those of the OVX group 
(p < 0.05). It is worth noting that the increase in 
maximum load observed for the H-RDE group 
was similar to that of E2 (p > 0.05). 
 
Table 1: Effect of RDE on bone mineral density (BMD) of L4 vertebrae and femur (n = 10) 
 
Group Dosage (mg/kg) BMD of vertebrae (g/cm3) BMD of femurs (g/cm3) 
Control - 0.22 ± 0.03* 0.19 ± 0.03* 
OVX - 0.16 ± 0.04 0.14 ± 0.04 
E2 0.025 0.20 ± 0.03* 0.18 ± 0.03* 
L-RDE 40 0.18 ± 0.02* 0.16 ± 0.02* 
M-RDE 80 0.19 ± 0.02* 0.17 ± 0.03* 
H-RDE 160 0.20 ± 0.02* 0.18 ± 0.02* 
*P < 0.05 and **p < 0.01 versus OVX group. L-RDE: low dose of RDE, M-RDE: middle dose of RDE, H-RDE: high 
dose of RDE 
 
Table 2: Effect of RDE on femur mechanical properties (n = 10) 
 
Group Dosage (mg/kg) Maximum load (N) Maximum stress (MPa) 
Control - 124.7 ± 5.6* 198.4 ± 6.3* 
OVX - 92.5 ± 4.8 154.2 ± 5.8 
E2 0.025 116.3 ± 5.2* 183.6 ± 5.1* 
L-RDE 40 95.1 ± 4.9 157.2 ± 4.9 
M-RDE 80 105.3 ± 5.5* 172.3 ± 5.3* 
H-RDE 160 112.4 ± 5.1* 178.6 ± 5.5* 
*P < 0.05 and **p < 0.01 versus OVX group.L-RDE: low dose of RDE, M-RDE: middle dose of RDE, H-RDE: high 
dose of RDE 
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Micro-CT data for L4 vertebrae 
 
Analysis of the representative samples (Table 3) 
indicated that OVX resulted in the deterioration of 
the trabecular bone microarchitecture, as 
demonstrated by the reduced Tb-N and Tb-Th 
compared with the sham group (both p < 0.05). 
In contrast, Tb-Sp was significantly increased in 
response to OVX compared to the sham group (p 
< 0.05). Higher dosage of RDE treatment (80 or 
160 mg/kg/day) significantly improved the 
microarchitecture deterioration mentioned above 
(p < 0.05), while E2 also reversed these 
parameters to the similar degree as that in the H-
RDE group (p > 0.05). 
 
Biochemical profile of serum and urine 
specimens 
 
Data presented in Table 4 show the effect of 
RDE on biochemical parameters in the serum 
and urine of OVX rats. Serum U-Ca/Cr, U-P/Cr, 
ALP, and OC levels were significantly increased 
in the OVX group compared to the sham group 
(p < 0.05). All three RDE doses significantly 
decreased the U-Ca/Cr and ALP levels (p < 0.05) 
in a dose-dependent manner. Higher dosage of 
RDE treatment (80 or 160 mg/kg/day) decreased 
the U-P/Cr and OC levels (p < 0.05). Again, E2 
administration also reversed these increases 
which were statistically significant. It is worth 
noting that the reductions in U-P/Cr, ALP, and 
OC in the H-RDE group were similar to those 
observed for E2 (all p > 0.05). 
DISCUSSION 
 
The high incidence, serious complications, 
financial burden, and dramatically decreased 
living quality indicate the severity of osteoporosis 
in humans. Despite the pharmacological and 
clinical advantages of HRT as a widely accepted 
therapeutic strategy for osteoporosis, serious 
side effects of long-term application have also 
been reported. Therefore, the development of 
new preventive and therapeutic drugs for 
osteoporosis is urgently needed. In recent 
decades, Chinese medicinal herbal extracts have 
been extensively investigated for their 
pharmacological effects related to bone 
protection. Bone remodeling is the biologic 
process that mediates changes in the traits that 
influence bone strength [1]. Any interruption in 
bone remodeling, such as menopause, will 
disturb the balance between formation and 
resorption and cause bone mass loss [21-22]. 
Therefore, we used OVX rats as an animal 
model for human osteoporosis in vivo 
experiments. It has been reported that 
statistically significant bone loss can be seen 
after 30 days [23], so treatment was initiated 4 
weeks after OVX. Consistent with other studies, 
OVX caused significantly higher body weights in 
our present study, which may be attributed to fat 
deposition caused by the lack of estrogen [24]. 
Previous studies suggest that estrogen plays an 
important role in stimulating the differentiation of 
progenitor cells through the osteoblast lineage 
but not the adipocyte lineage [25].
Table 3: Effect of RDE on morphometric parameters in L4 vertebrae (n = 10) 
 
Group Dosage (mg/kg) Tb-N (1/mm) Tb-Th (mm) Tb-Sp (mm) 
Control - 4.5±0.3* 0.097±0.014* 0.14±0.01* 
OVX - 2.5±0.4 0.065±0.012 0.33±0.03 
E2 0.025 4.1±0.4* 0.088±0.013* 0.18±0.01* 
L-RDE 40 2.8±0.4 0.067±0.014 0.27±0.02 
M-RDE 80 3.4±0.3* 0.077±0.012* 0.23±0.02* 
H-RDE 160 3.8±0.2* 0.083±0.011* 0.19±0.01* 
*P < 0.05 and **p < 0.01 versus OVX group. L-RDE: low dose of RDE, M-RDE: middle dose of RDE, H-RDE: high 
dose of RDE 
 
Table 4: Effect of RDE on biochemical parameters in the serum and urine (n = 10) 
 
Group Dosage (mg/kg) U-Ca/Cr(mmol/mmol) U-P/Cr(mmol/mmol) ALP(U/L) OC(mmol/L) 
Control - 0.22±0.02* 3.8±0.3* 112.5±11.1* 8.1±0.2* 
OVX - 0.45±0.04 5.6±0.3 227.3±28.6 12.3±0.4 
E2 0.025 0.26±0.02* 4.1±0.2* 140.1±19.7* 9.2±0.3* 
L-RDE 40 0.38±0.0.02* 5.2±0.5 163.4±15.8* 10.8±0.4 
M-RDE 80 0.34±0.01* 4.5±0.4* 156.7±14.9* 10.2±0.2* 
H-RDE 160 0.29±0.0.02* 4.3±0.3* 145.4±16.1* 9.6±0.2* 
*P < 0.05 and **p < 0.01 versus OVX group. L-RDE: low dose of RDE, M-RDE: middle dose of RDE, H-RDE: high 
dose of RDE 
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Decreased BMD is one of the major factors 
jeopardizing bone strength, resulting in increased 
susceptibility to fractures [26]. Thus, BMD 
measurement can best predict fracture risk [27]. 
The results in the present study showed that 
OVX reduced BMD in the right femurs and L4 
vertebrae, which are rich in trabecular bone, 
while treatment with RDE dose-dependently 
prevented the decreases in BMD. Although BMD 
is among the strongest predictors of facture 
resistance, both empirical observations and 
theoretical analyses show that the biomechanical 
properties of bone and trabecular 
microarchitecture influence trabecular bone 
strength as well [28-30]. Three-point bending 
tests of the left femurs in our study indicated that 
the higher croc in doses (80 or 160 mg/kg/day) 
prevented the OVX-induced tendency toward 
decreased biomechanical parameters. 
 
Moreover, measurements of structural 
parameters using micro-CT also showed that 
treatment with RDE effectively restored the 
trabecular micro architectural properties 
compared to the OVX group. In addition, 
measurement of bone markers plays a role in 
osteoporosis diagnosis and treatment [31]. Bone 
mass loss, as evidenced by enhanced levels of 
ALP, OC, U-Ca/Cr, and U-P/Cr, indicated 
upregulation of bone turnover by OVX. The bone 
turnover markers above were dose-dependently 
reversed by RDE, indicating a reduction in bone 
turnover rate after treatment of RDE. Our results 
suggested RDE’s effectiveness in treating 




This study demonstrate that daily oral 
administration of RDE over a 12-week period 
prevents estrogen deficiency-induced bone loss, 
inhibits the deterioration of trabecular 
microarchitecture, maintains the biomechanical 
competence of bone, decreases bone turnover 
rate, and does not stimulate an unwanted 
proliferation of the uterine tissues. Our findings 
indicate that RDE has the potential to be further 
developed as a natural alternative for 
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